Skip to main content
eScholarship
Open Access Publications from the University of California

Scholarly Works (9 results)

  • Article
  • Peer Reviewed
LBL Publications (2008)

We construct the microstates of near-extremal black holes in AdS_5 x S5 as gases of defects distributed in heavy BPS operators in the dual SU(N) Yang-Mills theory. These defects describe open strings on spherical D3-branes in the S5, and we show that they dominate the entropy by directly enumerating them and comparing the results with a partition sum calculation. We display new decoupling limits in which the field theory of the lightest open strings on the D-branes becomes dual to a near-horizon region of the black hole geometry. In the single-charge black hole we find evidence for an infrared duality between SU(N) Yang-Mills theories that exchanges the rank of the gauge group with an R-charge. In the two-charge case (where pairs of branes intersect on a line), the decoupled geometry includes an AdS_3 factor with a two-dimensional CFT dual. The degeneracy in this CFT accounts for the black hole entropy. In the three-charge case (where triples of branes intersect at a point), the decoupled geometry contains an AdS_2 factor. Below a certain critical mass, the two-charge system displays solutions with naked timelike singularities even though they do not violate a BPS bound. We suggest a string theoretic resolution of these singularities.

    Cover page: Entropy of near-extremal black holes in AdS5
    • Article
    • Peer Reviewed
    LBL Publications (2008)

    Most quantum states have wavefunctions that are widely spread over the accessible Hilbert space and hence do not have a good description in terms of a single classical geometry. In order to understand when geometric descriptions are possible, we exploit the AdS/CFT correspondence in the half-BPS sector of asymptotically AdS_5 x S5 universes. In this sector we devise a "coarse-grained metric operator" whose eigenstates are well described by a single spacetime topology and geometry. We show that such half-BPS universes have a non-vanishing entropy if and only if the metric is singular, and that the entropy arises from coarse-graining the geometry. Finally, we use our entropy formula to find the most entropic spacetimes with fixed asymptotic moments beyond the global charges.

      Cover page: Quantum geometry and gravitational entropy
      • Article
      • Peer Reviewed
      UC Santa Barbara Previously Published Works (2006)
      We argue that if black hole entropy arises from a finite number of underlying quantum states, then any particular such state can be identified from infinity. The finite density of states implies a discrete energy spectrum, and, in general, such spectra are non-degenerate except as determined by symmetries. Therefore, knowledge of the precise energy, and of other commuting conserved charges, determines the quantum state. In a gravitating theory, all conserved charges including the energy are given by boundary terms that can be measured at infinity. Thus, within any theory of quantum gravity, no information can be lost in black holes with a finite number of states. However, identifying the state of a black hole from infinity requires measurements with Planck scale precision. Hence observers with insufficient resolution will experience information loss.
        Cover page: Information Recovery From Black Holes
        • Article
        • Peer Reviewed
        UC Berkeley Previously Published Works (2024)
        Multiple lines of evidence suggest that the Hilbert space of an isolated de Sitter universe is one dimensional but can appear larger when probed by a gravitating observer. To test this idea, we compute the von Neumann entropy of a field theory in a two-dimensional de Sitter universe which is entangled in a thermal-like state with the same field theory on a disjoint, asymptotically anti-de Sitter (AdS) black hole. Previously, it was shown that the replica trick for computing the entropy of such entangled gravitating systems requires the inclusion of a non-perturbative effect in quantum gravity — novel wormholes connecting the two spaces. Here we show that: (a) the expected wormholes connecting de Sitter and AdS universes exist, avoiding a no-go theorem via the presence of sources on the AdS boundary; (b) the entanglement entropy vanishes if the nominal entropy of the de Sitter cosmological horizon SdS=AhorizondS/4GN is less than the entropy of the AdS black hole horizon SBH=AhorizonAdS/4GN, i.e., SdS< SBH; (c) the entanglement entropy is finite when SdS > SBH. Thus, the de Sitter Hilbert space is effectively nontrivial only when SdS > SBH. The AdS black hole we introduce can be regarded as an “observer” for de Sitter space. In this sense, our result is a non-perturbative generalization of the recent perturbative argument that the algebra of observables on the de Sitter static patch becomes nontrivial in the presence of an observer.
          Cover page: De Sitter space is sometimes not emptyCreative Commons 'BY' version 4.0 license
          • Article
          • Peer Reviewed
          UC Santa Barbara Previously Published Works (2014)
          The AdS/CFT correspondence relates quantum entanglement between boundary conformal field theories and geometric connections in the dual asymptotically anti-de Sitter spacetime. We consider entangled states in the n-fold tensor product of a 1 + 1 dimensional CFT Hilbert space defined by the Euclidean path integral over a Riemann surface with n holes. In one region of moduli space, the dual bulk state is a black hole with n asymptotically AdS3 regions connected by a common wormhole, while in other regions the bulk fragments into disconnected components. We study the entanglement structure and compute the wave function explicitly in the puncture limit of the Riemann surface in terms of CFT n-point functions. We also use AdS minimal surfaces to measure entanglement more generally. In some regions of the moduli space the entanglement is entirely multipartite, though not of the GHZ type. However, even when the bulk is completely connected, there are regions of the moduli space in which the entanglement is instead almost entirely bipartite: significant entanglement occurs only between pairs of CFTs. We develop new tools to analyze intrinsically n-partite entanglement, and use these to show that for some wormholes with n similar sized horizons there is intrinsic entanglement between all n parties, and that the distillable entanglement between the asymptotic regions is at least (n + 1)/2 partite.
            Cover page: Multiboundary wormholes and holographic entanglement
            • Article
            • Peer Reviewed
            UC Davis Previously Published Works (2017)
            In patients treated with macitentan (Opsumit®, Actelion Pharmaceuticals Ltd., Basel, Switzerland) for pulmonary arterial hypertension (PAH), prevention and/or effective management of treatment-related adverse events may improve adherence. However, management of these adverse events can be challenging and the base of evidence and clinical experience for macitentan is limited. In the absence of evidence, consensus recommendations from physicians experienced in using macitentan to treat PAH may benefit patients and physicians who are using macitentan. Consensus recommendations were developed by a panel of physicians experienced with macitentan and PAH using a modified Delphi process. Over three iterations, panelists developed and refined a series of statements on the use of macitentan in PAH and rated their agreement with each statement on a Likert scale. The panel of 18 physicians participated and developed a total of 118 statements on special populations, add-on therapy, drug-drug interactions, warnings and precautions, hospitalization and functional class, and adverse event management. The resulting consensus recommendations are intended to provide practical guidance on real-world issues in using macitentan to treat patients with PAH.
              Cover page: Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document.
              • Article
              • Peer Reviewed
              UC Davis Previously Published Works (2022)
              Dual combination therapy with a phosphodiesterase-5 inhibitor (PDE5i) and endothelin receptor antagonist is recommended for most patients with intermediate-risk pulmonary arterial hypertension (PAH). The RESPITE and REPLACE studies suggest that switching from a PDE5i to a soluble guanylate cyclase (sGC) activator may provide clinical improvement in this situation. The optimal approach to escalation or transition of therapy in this or other scenarios is not well defined. We developed an expert consensus statement on the transition to sGC and other treatment escalations and transitions in PAH using a modified Delphi process. The Delphi process used a panel of 20 physicians with expertise in PAH. Panelists answered three questionnaires on the management of treatment escalations and transitions in PAH. The initial questionnaire included open-ended questions. Later questionnaires consolidated the responses into statements that panelists rated on a Likert scale from -5 (strongly disagree) to +5 (strongly agree) to determine consensus. The Delphi process produced several consensus recommendations. Escalation should be considered for patients who are at high risk or not achieving treatment goals, by adding an agent from a new class, switching from oral to parenteral prostacyclins, or increasing the dose. Switching to a new class or within a class should be considered if tolerability or other considerations unrelated to efficacy are affecting adherence. Switching from a PDE5i to an SGC activator may benefit patients with intermediate risk who are not improving on their present therapy. These consensus-based recommendations may be helpful to clinicians and beneficial for patients when evidence-based guidance is unavailable.
                Cover page: Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat
                • Article
                • Peer Reviewed
                UC San Francisco Previously Published Works (2022)
                Despite numerous therapeutic advances in pulmonary arterial hypertension, patients continue to suffer high morbidity and mortality, particularly considering a median age of 50 years. This article explores whether early, robust reduction of right ventricular afterload would facilitate substantial improvement in right ventricular function and thus whether afterload reduction should be a treatment goal for pulmonary arterial hypertension. The earliest clinical studies of prostanoid treatment in pulmonary arterial hypertension demonstrated an important link between lowering mean pulmonary arterial pressure (or pulmonary vascular resistance) and improved survival. Subsequent studies of oral monotherapy or sequential combination therapy demonstrated smaller reductions in mean pulmonary arterial pressure and pulmonary vascular resistance. More recently, retrospective reports of initial aggressive prostanoid treatment or initial combination oral and parenteral therapy have shown marked afterload reduction along with significant improvements in right ventricular function. Some data suggest that reaching threshold levels for pressure or resistance (components of right ventricular afterload) may be key to interrupting the self-perpetuating injury of pulmonary vascular disease in pulmonary arterial hypertension and could translate into improved long-term clinical outcomes. Based on these clues, the authors postulate that improved clinical outcomes might be achieved by targeting significant afterload reduction with initial oral combination therapy and early parenteral prostanoids.
                  Cover page: Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?
                  • Article
                  • Peer Reviewed
                  UC Davis Previously Published Works (2020)
                  Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown.Objectives: To evaluate the effect of oral treprostinil compared with placebo on time to first adjudicated clinical worsening event in participants with PAH who recently began approved oral monotherapy.Methods: In this event-driven, double-blind study, we randomly allocated 690 participants (1:1 ratio) with PAH to receive placebo or oral treprostinil extended-release tablets three times daily. Eligible participants were using approved oral monotherapy for over 30 days before randomization and had a 6-minute-walk distance 150 m or greater. The primary endpoint was the time to first adjudicated clinical worsening event: death; hospitalization due to worsening PAH; initiation of inhaled or parenteral prostacyclin therapy; disease progression; or unsatisfactory long-term clinical response.Measurements and Main Results: Clinical worsening occurred in 26% of the oral treprostinil group compared with 36% of placebo participants (hazard ratio, 0.74; 95% confidence interval, 0.56-0.97; P = 0.028). Key measures of disease status, including functional class, Borg dyspnea score, and N-terminal pro-brain natriuretic peptide, all favored oral treprostinil treatment at Week 24 and beyond. A noninvasive risk stratification analysis demonstrated that oral treprostinil-assigned participants had a substantially higher mortality risk at baseline but achieved a lower risk profile from Study Weeks 12-60. The most common adverse events in the oral treprostinil group were headache, diarrhea, flushing, nausea, and vomiting.Conclusions: In participants with PAH, addition of oral treprostinil to approved oral monotherapy reduced the risk of clinical worsening.Clinical trial registered with www.clinicaltrials.gov (NCT01560624).
                    Cover page: Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial
                    Top